Folic acid-conjugated graphene oxide as a transporter of chemotherapeutic drug and siRNA for reversal of cancer drug resistance

Cao, Xiufen; Feng, Fuli; Wang, Yinsong; Yang, Xiaoying; Duan, Hong‐Quan; Chen, Yongshen

doi:10.1007/s11051-013-1965-y

Cited by 32 publications

(17 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The transfection of MDR1 siRNA by GO-FACO + significantly downregulates the MDR1 mRNA as well as P-gp (P-glycoprotein) protein expression level compared to the nontargeted controls evaluated using real time polymerase chain reaction and Western blot assay, respectively. Cellular uptake of DOX and MDR1 siR-NAs by GO-FACO + resulted in an increase in drug toxicity in MCF-7/DOX cells [137].…”

Section: Fr-mediated Graphene-based Nanoparticlesmentioning

confidence: 97%

See 1 more Smart Citation

Folate Receptor-Mediated siRNA Delivery: Recent Developments and Future Directions for RNAi Therapeutics

Gangopadhyay

Nikam

Gore

2021

Nucleic Acid Therapeutics

View full text Add to dashboard Cite

RNA interference (RNAi), a gene regulatory process mediated by small interfering RNAs (siRNAs), has made remarkable progress as a potential therapeutic agent against various diseases. However, RNAi is associated with fundamental challenges such as poor systemic delivery and susceptibility to the nucleases. Targeting ligand-bound delivery vehicles has improved the accumulation of drug at the target site, which has resulted in high transfection efficiency and enhanced gene silencing. Recently, folate receptor (FR)-mediated targeted delivery of siRNAs has garnered attention due to their enhanced cellular uptake and high transfection efficiency toward tumor cells. Folic acid (FA), due to its small size, low immunogenicity, high in vivo stability, and high binding affinity toward FRs, has attracted much attention for targeted siRNA delivery. FRs are overexpressed in a large number of tumors, including ovarian, breast, kidney, and lung cancer cells. In this review, we discuss recent advances in FA-mediated siRNA delivery to treat cancers and inflammatory diseases. This review summarizes various FA-conjugated nanoparticle systems reported so far in the literature, including liposome, silica, metal, graphene, dendrimers, chitosan, organic copolymers, and RNA nanoparticles. This review will help in the design and development of potential delivery vehicles for siRNA drug targeting to tumor cells using an FR-mediated approach.

show abstract

Section: Fr-mediated Graphene-based Nanoparticlesmentioning

confidence: 97%

“…Cao et al reported the GO-based delivery carrier conjugated to FA and chitosan oligosaccharides for combinational therapy of MDR1-targeted siRNA and DOX to breast cancer (MCF-7) cells ( Fig. 5b) [137]. Intracellular uptake was investigated with the FA-conjugated GO (GO-FACO + ) assembly.…”

Section: Fr-mediated Graphene-based Nanoparticlesmentioning

confidence: 99%

Folate Receptor-Mediated siRNA Delivery: Recent Developments and Future Directions for RNAi Therapeutics

Gangopadhyay

Nikam

Gore

2021

Nucleic Acid Therapeutics

View full text Add to dashboard Cite

show abstract

“…44 The combination of FA made the absorption peak of GO shift to 234 nm, and a new absorption peak appeared at 209 nm (Figure 2(c)). 45 The combination of Tf weakened the strength of all absorption and was accompanied by a new absorption peak at 250 nm and caused the end of absorption (Figure 2(d)). The FT-IR was used, and the results are shown in Figure 3 to further confirm that the product was successfully modified.…”

Section: Characterizationmentioning

confidence: 99%

Preparation and anti-cancer activity of transferrin/folic acid double-targeted graphene oxide drug delivery system

Nong

Wei

et al. 2020

J Biomater Appl

View full text Add to dashboard Cite

In this study, a transferrin/folic acid double-targeting graphene oxide drug delivery system loaded with doxorubicin was designed. Graphene oxide was prepared by ultrasound improved Hummers method and was modified with Pluronic F68, folic acid, and transferrin to decrease its toxicity and to allow dual-targeting. The results show that the double target drug delivery system (TFGP*DOX) has good and controllable drug delivery performance with no toxicity. Moreover, TFGP*DOX has a better inhibitory effect on SMMC-7721 cells than does a single target drug delivery system (FGP*DOX). The results of drug release analysis and cell inhibition studies showed that TFGP*DOX has a good sustained release function that can reduce the drug release rate in blood circulation over time and improve the local drug concentration in or near a targeted tumor. Therefore, the drug loading system (TFGP*DOX) has potential application value in the treatment of hepatocellular carcinoma.

show abstract

“…As a tumor marker overexpressed in more than 90% of ovarian carcinomas, folate receptor (FR) has been widely used as an efficient molecular target for tumor therapy. 40 We investigated the cytotoxicity and FR expression levels of FR-positive HeLa cell lines and FR-negative SMMC-7721 and normal NIH-3T3 cell lines. As shown in Fig.…”

Section: Biocompatibility and The Immune Evading Ability Of Scpb@dox@mentioning

confidence: 99%

An erythrocyte membrane coated mimetic nano-platform for chemo-phototherapy and multimodal imaging

et al. 2019

View full text Add to dashboard Cite

show abstract

Folic acid-conjugated graphene oxide as a transporter of chemotherapeutic drug and siRNA for reversal of cancer drug resistance

Cited by 32 publications

References 16 publications

Folate Receptor-Mediated siRNA Delivery: Recent Developments and Future Directions for RNAi Therapeutics

Folate Receptor-Mediated siRNA Delivery: Recent Developments and Future Directions for RNAi Therapeutics

Preparation and anti-cancer activity of transferrin/folic acid double-targeted graphene oxide drug delivery system

An erythrocyte membrane coated mimetic nano-platform for chemo-phototherapy and multimodal imaging

Contact Info

Product

Resources

About